Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 May 6;27(5):e420-e421.
doi: 10.1093/oncolo/oyac057.

Concordance of Blood-Based and Normal Tissue-Based Dihydropyrimidine Dehydrogenase (DPYD) Genotyping

Cristina Morelli  1 , Vincenzo Formica  1 , Elena Doldo  2 , Silvia Riondino  1 , Michela Rofei  1 , Lorena Vergilii  2 , Giampiero Palmieri  2 , Hendrik-Tobias Arkenau  3 , Mario Roselli  1 , Augusto Orlandi  2
Affiliations
Comment

Concordance of Blood-Based and Normal Tissue-Based Dihydropyrimidine Dehydrogenase (DPYD) Genotyping

Cristina Morelli et al. Oncologist. .

Abstract

In response to the recently published article by Sharma et al, this letter to the editor presents data about the concordance of blood and normal tissue-based evaluation of DPYD genotyping that suggests that pharmacogenetic screening could be contextual to tumor molecular profiling.

PubMed Disclaimer

Comment in

  • In Reply.
    Rai K, Brooks G. Rai K, et al. Oncologist. 2022 May 6;27(5):e422. doi: 10.1093/oncolo/oyac058. Oncologist. 2022. PMID: 35325206 Free PMC article.

Comment on

References

    1. Sharma BB, Rai K, Blunt H, et al. . Pathogenic DPYD variants and treatment-related mortality in patients receiving fluoropyrimidine chemotherapy: a systematic review and meta-analysis. Oncologist 2021;26(12):1008-1016. - PMC - PubMed
    1. Henricks LM, Lunenburg CATC, de Man FM, et al. . DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol. 2018;19(11):1459-1467. - PubMed
    1. Hodroj K, Barthelemy D, Lega JC, et al. . Issues and limitations of available biomarkers for fluoropyrimidine-based chemotherapy toxicity, a narrative review of the literature. ESMO Open 2021;6(3):100125. - PMC - PubMed
    1. European Medicines Agency. 5-Fluorouracil (i.v.), capecitabine and tegafur containing products: pre-treatment testing to identify DPD deficient patients at increased risk of severe toxicity. Available at https://www.ema.europa.eu/en/medicines/dhpc/5-fluorouracil-iv-capecitabi.... Accessed September 28, 2021
    1. USFDA. Table of Pharmacogenetic Associations. FDA. 2020. Available at: https://www.fda.gov/medical-devices/precision-medicine/tablepharmacogene.... Accessed October 18, 2021